+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
SAAKSHI

Saakshi Medtech & Panels Share Price

 

 

Saakshi Medtech & Panels live price: ₹305. It opened at ₹312 vs previous close ₹309; intraday high/low: ₹313/₹300. The 50 & 200 DMA stand at ₹243.57/₹206.30.

Saakshi Medtech & Panels Performance

  • Today's Low
  • ₹300
  • Today's High
  • ₹313
  • 52 Week Low
  • ₹147
  • 52 Week High
  • ₹318
  • Open Price₹312
  • Previous Close₹309
  • Volume33,600
  • 50 DMA₹243.57
  • 100 DMA₹223.47
  • 200 DMA₹206.30

Saakshi Medtech & Panels Chart

Investment Returns

  • Over 1 Month + 33.01%
  • Over 3 Month + 60.57%
  • Over 6 Month + 62.28%
  • Over 1 Year + 82.69%

Smart Investing Starts Here Start SIP with Saakshi Medtech & Panels for Steady Growth!

Invest Now

Saakshi Medtech & Panels Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 43.8
  • PEG Ratio
  • -
  • Market Cap Cr
  • 539
  • P/B Ratio
  • 4.9
  • Average True Range
  • 13.38
  • EPS
  • 6.96
  • Dividend Yield
  • 0
  • MACD Signal
  • 11.1
  • RSI
  • 77.69
  • MFI
  • 84.85

Latest Stock News Updates

Saakshi Medtech shares make stellar debut, stock lists at 50.5% premium at 146 on NSE SME

Saakshi Medtech shares make stellar debut on NSE SME, listed at 146 per share, 50.5% higher than issue price of 97.

Saakshi Medtech & Panels Financials

Saakshi Medtech & Panels Technicals

EMA & SMA

Current Price
₹305.00
-3.65 (-1.18%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹265.80
  • 50 Day
  • ₹243.60
  • 100 Day
  • ₹223.50
  • 200 Day
  • ₹206.30

Resistance and Support

306.08 Pivot Speed
  • R3 324.67
  • R2 318.83
  • R1 311.92
  • S1 299.17
  • S2 293.33
  • S3 286.42

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Saakshi Medtech And Panels Ltd has an operating revenue of Rs. 281.82 Cr. on a trailing 12-month basis. An annual revenue growth of 25% is outstanding, Pre-tax margin of 14% is healthy, ROE of 11% is good. The company has a reasonable debt to equity of 15%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 26% and 56% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 10% from the pivot point (which is extended from the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 81 which is a GOOD score indicating consistency in earnings, a RS Rating of 94 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 53 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of B is close to being the best. Overall, the stock has great fundamentals and technical strength to stay in momentum.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Saakshi Medtech & Panels Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-05-26 Audited Results
2026-05-07 To consider Fund Raising
2025-11-14 Quarterly Results
2024-11-13 Quarterly Results
2024-05-28 Audited Results

Saakshi Medtech & Panels Shareholding Pattern

74.82%
0.07%
21.17%
3.94%

Saakshi Medtech & Panels FAQs

Saakshi Medtech & Panels share price is ₹305 As on 27 June, 2026 | 22:34

The Market Cap of Saakshi Medtech & Panels is ₹538.5 Cr As on 27 June, 2026 | 22:34

The P/E ratio of Saakshi Medtech & Panels is 43.8 As on 27 June, 2026 | 22:34

The PB ratio of Saakshi Medtech & Panels is 4.9 As on 27 June, 2026 | 22:34

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23